Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Dosing Timing in Type 2 Diabetes
NCT00359879Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2006
- Primary completion
- Jul 2007
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Sep 2006; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00359879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00359879.